| P50 | author | Simon P Robinson | Q37383651 |
| | Jessica K R Boult | Q87609562 |
| P2093 | author name string | Andrew R Reynolds | |
| | Naveen S Vasudev | |
| P2860 | cites work | Modes of resistance to anti-angiogenic therapy | Q24608005 |
| | Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentiality | Q27025007 |
| | Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma | Q28247085 |
| | Sunitinib versus interferon alfa in metastatic renal-cell carcinoma | Q28282757 |
| | Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research | Q29547313 |
| | Imaging biomarker roadmap for cancer studies | Q30242020 |
| | Do imaging biomarkers relate to outcome in patients treated with VEGF inhibitors? | Q30574516 |
| | Effects of overexpression of dimethylarginine dimethylaminohydrolase on tumor angiogenesis assessed by susceptibility magnetic resonance imaging. | Q33188292 |
| | Susceptibility contrast magnetic resonance imaging determination of fractional tumor blood volume: a noninvasive imaging biomarker of response to the vascular disrupting agent ZD6126. | Q33299990 |
| | Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial | Q33750154 |
| | Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions | Q33770680 |
| | Non-invasive in vivo imaging of vessel calibre in orthotopic prostate tumour xenografts | Q33863907 |
| | Guidelines for the welfare and use of animals in cancer research | Q33903753 |
| | Active site mutant dimethylarginine dimethylaminohydrolase 1 expression confers an intermediate tumour phenotype in C6 gliomas. | Q33904265 |
| | Evaluation of novel combined carbogen USPIO (CUSPIO) imaging biomarkers in assessing the antiangiogenic effects of cediranib (AZD2171) in rat C6 gliomas. | Q34145257 |
| | Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging | Q34319385 |
| | Combretastatin A-4 phosphate affects tumor vessel volume and size distribution as assessed using MRI-based vessel size imaging | Q34446566 |
| | Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma | Q34495684 |
| | Sunitinib and other targeted therapies for renal cell carcinoma | Q34621802 |
| | Applications of ultrasmall superparamagnetic iron oxide contrast agents in the MR study of animal models. | Q35939112 |
| | Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. | Q35966757 |
| | Contrasting effects of sunitinib within in vivo models of metastasis | Q36394262 |
| | Validation of the fluorescent dye Hoechst 33342 as a vascular space marker in tumours | Q36450490 |
| | Oxygen-Enhanced MRI Accurately Identifies, Quantifies, and Maps Tumor Hypoxia in Preclinical Cancer Models | Q36591139 |
| | Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model? | Q37205008 |
| | Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma | Q37331117 |
| | Resistance to targeted therapy in renal-cell carcinoma | Q37606744 |
| | MRI with ferumoxytol: A single center experience of safety across the age spectrum | Q37622520 |
| | Emerging applications for ferumoxytol as a contrast agent in MRI. | Q38224182 |
| | Imaging intratumor heterogeneity: role in therapy response, resistance, and clinical outcome. | Q38271116 |
| | Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma | Q38826287 |
| | Bayesian estimation of changes in transverse relaxation rates | Q39661405 |
| | Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients. | Q39805218 |
| | Clinical translation of ferumoxytol-based vessel size imaging (VSI): Feasibility in a phase I oncology clinical trial population | Q39966046 |
| | Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT. | Q43020663 |
| | Pretreatment assessment of tumor enhancement on contrast-enhanced computed tomography as a potential predictor of treatment outcome in metastatic renal cell carcinoma patients receiving antiangiogenic therapy. | Q43131963 |
| | Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. | Q43211383 |
| | The loss of radiographic enhancement in primary renal cell carcinoma tumors following multitargeted receptor tyrosine kinase therapy is an additional indicator of response | Q43237391 |
| | Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma. | Q46395435 |
| | Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma | Q46792167 |
| | Patupilone induced vascular disruption in orthotopic rodent tumor models detected by magnetic resonance imaging and interstitial fluid pressure | Q46797222 |
| | In vivo assessment of tumoral angiogenesis. | Q47990042 |
| | Hemodynamic safety and efficacy of ferumoxytol as an intravenous contrast agents in pediatric patients and young adults. | Q53405001 |
| | Antiangiogenic tumor treatment: early noninvasive monitoring with USPIO-enhanced MR imaging in mice | Q80465220 |
| | Measuring response in a post-RECIST world: from black and white to shades of grey | Q83190877 |
| | Tumor blood volume determination by using susceptibility-corrected DeltaR2* multiecho MR | Q84300035 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | renal cell carcinoma | Q1164529 |
| P577 | publication date | 2017-05-31 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Monitoring the vascular response and resistance to sunitinib in renal cell carcinoma in vivo with susceptibility contrast MRI. | |